Edison healthcare quarterly: Boom times for US biotech

The book opens with an overview from Christian Glennie. He writes that discrepancies in valuation and finance between the European and US healthcare markets has long been marked, but 2012 has seen the gap grow ever wider. While the NASDAQ Biotechnology Index now matches the highs of the dot.com boom in 2000, European equivalent indices show modest gains. The European pharma/biotech sector has often lagged the US, but with opposing trends in drug prices, IPOs and venture/public equity financing, a significant turnaround is required while European economic shackles will be tough to break. Yet with the US likely to build further on an encouraging year in 2012, we remain hopeful the European market will benefit from the US biotech boom.

Download PDF